Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis

European Journal of Neurology

Volumn 19, Issue 4, 2012, Pages 616-624

  D'hooghe, M B ^a   Haentjens, P ^b   Nagels, G ^a,c   De Keyser, J ^b,d  

^a National MS Center Melsbroek   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY OF MONS   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Lifestyle; Multiple sclerosis; Progression

Indexed keywords

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLIC BEVERAGE; ARTICLE; BELGIUM; BIRTH; CIGARETTE SMOKING; COFFEE; CROSS-SECTIONAL STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FISH; FOOD INTAKE; FOOD PREFERENCE; GENDER; HAZARD RATIO; HEALTH SURVEY; HUMAN; HYPOTHESIS; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TEA; WINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANIMALS; BELGIUM; COFFEE; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FISHES; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84858332372     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03596.x     Document Type: Article

References (39)

1. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277.
2. D'Hooghe MB, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 2010; 16: 773-785.
3. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66: 858-864.
4. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler 1999; 5: 78-88.
5. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol 1995; 142: 733-737.
6. Lauer K. Diet and multiple sclerosis. Neurology 1997; 49: S55-S61.
7. Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004; 24: 1521-1529.
8. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004; 173: 5794-5800.
9. Wilkins A, Scolding N. Protecting axons in multiple sclerosis. Mult Scler 2008; 14: 1013-1025.
10. van Ooteghem P, D'Hooghe MB, Vlietinck R, Carton H. Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology 1994; 13: 220-225.
11. Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006; 7(Suppl 2): S24-S33.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
13. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999; 5: 349-354.
14. Mukamal KJ, Chung H, Jenny NS, et al. Alcohol consumption and risk of coronary heart disease in older adults: the Cardiovascular Health Study. J Am Geriatr Soc 2006; 54: 30-37.
15. Ganguli M, Vander Bilt J, Saxton JA, Shen C, Dodge HH. Alcohol consumption and cognitive function in late life: a longitudinal community study. Neurology 2005; 65: 1210-1217.
16. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009; 5: 140-152.
17. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65: 1409-1414.
18. Pekmezovic T, Drulovic J, Milenkovic M, et al. Lifestyle factors and multiple sclerosis: a case-control study in Belgrade. Neuroepidemiology 2006; 27: 212-216.
19. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007; 254: 471-477.
20. Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000; 152: 1056-1064.
21. Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 2005; 352: 245-253.
22. Imhof A, Woodward M, Doering A, et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 2004; 25: 2092-2100.
23. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 2140-2146.
24. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010; 636: 1-7.
25. Horrigan LA, Kelly JP, Connor TJ. Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol 2004; 4: 1409-1417.
26. Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006; 248: 9-15.
27. de Mejia EG, Ramirez-Mares MV, Puangpraphant S. Bioactive components of tea: cancer, inflammation and behavior. Brain Behav Immun 2009; 23: 721-731.
28. Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009; 66: 1169-1179.
29. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2007; 24: CD004192.
30. Bates D, Cartlidge NE, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52: 18-22.
31. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000; 102: 143-149.
32. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 2007; 69: 1515-1520.
33. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128: 1461-1465.
34. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009; 73: 504-510.
35. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34: J258-J265.
36. Bentzen J, Flachs EM, Stenager E, Bronnum-Hansen H, Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950--2005. Mult Scler 2010; 16: 520-525.
37. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler 2007; 13: 770-775.
38. Bowen J, Gibbons L, Gianas A, Kraft GH. Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler 2001; 7: 201-206.
39. Ingram G, Colley E, Ben-Shlomo Y, et al. Validity of patient-derived disability and clinical data in multiple sclerosis. Mult Scler 2010; 16: 472-479.